Loading…
Treatment of allergic rhinitis during pregnancy
Allergic rhinitis (AR) affecting approximately 20-30% of women in childbearing age can be considered one of the most common group of medical conditions that complicate pregnancy. AR with symptoms of nasal obstruction, sneezing, and itching may require pharmacotherapy. However, there are concerns reg...
Saved in:
| Published in: | American journal of rhinology 2004-01, Vol.18 (1), p.23-28 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233 |
| container_end_page | 28 |
| container_issue | 1 |
| container_start_page | 23 |
| container_title | American journal of rhinology |
| container_volume | 18 |
| creator | KeleSl, Nesil |
| description | Allergic rhinitis (AR) affecting approximately 20-30% of women in childbearing age can be considered one of the most common group of medical conditions that complicate pregnancy. AR with symptoms of nasal obstruction, sneezing, and itching may require pharmacotherapy. However, there are concerns regarding the safety of different available agents that can be used during pregnancy with respect to both maternal and fetal well being.
The best first-line approach in the management of AR is avoidance of allergens. If environmental modification is ineffective, then the pharmacologic agents should be chosen. For symptoms of rhinorrhea, sneezing, or itching, intranasal cromolyn, with its excellent safety profile, should be considered as first-line therapy. If cromolyn is ineffective or poorly tolerated, first-generation (e.g., chlorpheniramine and tripelennamine) and second generation (e.g., cetirizine and loratadine) antihistamines can be given. Intranasal steroids (e.g., beclomethasone dipropionate, and budesonide) can be added to first-line therapy especially for severe nasal obstruction. There are no epidemiological studies with newer intranasal steroids (e.g., flunisolide, triamcinolone acetonide, fluticasone propionate, and mometasone furoate) during the first trimester of pregnancy. Immunotherapy has not proven to be teratogenic and is clinically useful in improving symptoms. Oral and topical decongestants can be considered as second-line therapy, for short-term relief, when no safer alternative is available. |
| doi_str_mv | 10.1177/194589240401800106 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230846951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1350162891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233</originalsourceid><addsrcrecordid>eNplkD1PwzAQhi0EoqXwBxhQxB56tnMXe0QVBaRKLGWOnORSUuWj2MnQf09QKzEw3Ts873vSI8S9hCcp03QpbYLGqgQSkAZAAl2IuURtY1IWLqcMCDGhoZm4CWE_Iaky8lrMJIJGpHQullvPbmi5G6K-ilzTsN_VReS_6q4e6hCVo6-7XXTwvOtcVxxvxVXlmsB357sQn-uX7eot3ny8vq-eN3GhFQ0xS5tbJsUIrKnkSjMVJsE8L9khM-rSUGrJ2VJNXEG6IkyRXOKUQ6X1Qjyedg--_x45DNm-H303vcyUBpOQRTlB6gQVvg_Bc5UdfN06f8wkZL-Ksv-KptLDeXnMWy7_Kmcn-ge8H2AF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230846951</pqid></control><display><type>article</type><title>Treatment of allergic rhinitis during pregnancy</title><source>Sage Journals Online</source><creator>KeleSl, Nesil</creator><creatorcontrib>KeleSl, Nesil</creatorcontrib><description>Allergic rhinitis (AR) affecting approximately 20-30% of women in childbearing age can be considered one of the most common group of medical conditions that complicate pregnancy. AR with symptoms of nasal obstruction, sneezing, and itching may require pharmacotherapy. However, there are concerns regarding the safety of different available agents that can be used during pregnancy with respect to both maternal and fetal well being.
The best first-line approach in the management of AR is avoidance of allergens. If environmental modification is ineffective, then the pharmacologic agents should be chosen. For symptoms of rhinorrhea, sneezing, or itching, intranasal cromolyn, with its excellent safety profile, should be considered as first-line therapy. If cromolyn is ineffective or poorly tolerated, first-generation (e.g., chlorpheniramine and tripelennamine) and second generation (e.g., cetirizine and loratadine) antihistamines can be given. Intranasal steroids (e.g., beclomethasone dipropionate, and budesonide) can be added to first-line therapy especially for severe nasal obstruction. There are no epidemiological studies with newer intranasal steroids (e.g., flunisolide, triamcinolone acetonide, fluticasone propionate, and mometasone furoate) during the first trimester of pregnancy. Immunotherapy has not proven to be teratogenic and is clinically useful in improving symptoms. Oral and topical decongestants can be considered as second-line therapy, for short-term relief, when no safer alternative is available.</description><identifier>ISSN: 1050-6586</identifier><identifier>ISSN: 1945-8924</identifier><identifier>EISSN: 1539-6290</identifier><identifier>EISSN: 1945-8932</identifier><identifier>DOI: 10.1177/194589240401800106</identifier><identifier>PMID: 15035567</identifier><language>eng</language><publisher>United States: SAGE PUBLICATIONS, INC</publisher><subject>Administration, Oral ; Administration, Topical ; Adult ; Allergens ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - adverse effects ; Anti-Asthmatic Agents - therapeutic use ; Cromolyn Sodium - administration & dosage ; Cromolyn Sodium - adverse effects ; Cromolyn Sodium - therapeutic use ; Female ; Health Behavior ; Histamine H1 Antagonists - administration & dosage ; Histamine H1 Antagonists - adverse effects ; Histamine H1 Antagonists - therapeutic use ; Humans ; Immunotherapy ; Nasal Decongestants - administration & dosage ; Nasal Decongestants - adverse effects ; Nasal Decongestants - therapeutic use ; Pregnancy ; Pregnancy Complications - drug therapy ; Rhinitis, Allergic, Perennial - drug therapy</subject><ispartof>American journal of rhinology, 2004-01, Vol.18 (1), p.23-28</ispartof><rights>Copyright OceanSide Publications Jan 1, 2004</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233</citedby><cites>FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15035567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KeleSl, Nesil</creatorcontrib><title>Treatment of allergic rhinitis during pregnancy</title><title>American journal of rhinology</title><addtitle>Am J Rhinol</addtitle><description>Allergic rhinitis (AR) affecting approximately 20-30% of women in childbearing age can be considered one of the most common group of medical conditions that complicate pregnancy. AR with symptoms of nasal obstruction, sneezing, and itching may require pharmacotherapy. However, there are concerns regarding the safety of different available agents that can be used during pregnancy with respect to both maternal and fetal well being.
The best first-line approach in the management of AR is avoidance of allergens. If environmental modification is ineffective, then the pharmacologic agents should be chosen. For symptoms of rhinorrhea, sneezing, or itching, intranasal cromolyn, with its excellent safety profile, should be considered as first-line therapy. If cromolyn is ineffective or poorly tolerated, first-generation (e.g., chlorpheniramine and tripelennamine) and second generation (e.g., cetirizine and loratadine) antihistamines can be given. Intranasal steroids (e.g., beclomethasone dipropionate, and budesonide) can be added to first-line therapy especially for severe nasal obstruction. There are no epidemiological studies with newer intranasal steroids (e.g., flunisolide, triamcinolone acetonide, fluticasone propionate, and mometasone furoate) during the first trimester of pregnancy. Immunotherapy has not proven to be teratogenic and is clinically useful in improving symptoms. Oral and topical decongestants can be considered as second-line therapy, for short-term relief, when no safer alternative is available.</description><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Adult</subject><subject>Allergens</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Anti-Asthmatic Agents - adverse effects</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Cromolyn Sodium - administration & dosage</subject><subject>Cromolyn Sodium - adverse effects</subject><subject>Cromolyn Sodium - therapeutic use</subject><subject>Female</subject><subject>Health Behavior</subject><subject>Histamine H1 Antagonists - administration & dosage</subject><subject>Histamine H1 Antagonists - adverse effects</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Nasal Decongestants - administration & dosage</subject><subject>Nasal Decongestants - adverse effects</subject><subject>Nasal Decongestants - therapeutic use</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Rhinitis, Allergic, Perennial - drug therapy</subject><issn>1050-6586</issn><issn>1945-8924</issn><issn>1539-6290</issn><issn>1945-8932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNplkD1PwzAQhi0EoqXwBxhQxB56tnMXe0QVBaRKLGWOnORSUuWj2MnQf09QKzEw3Ts873vSI8S9hCcp03QpbYLGqgQSkAZAAl2IuURtY1IWLqcMCDGhoZm4CWE_Iaky8lrMJIJGpHQullvPbmi5G6K-ilzTsN_VReS_6q4e6hCVo6-7XXTwvOtcVxxvxVXlmsB357sQn-uX7eot3ny8vq-eN3GhFQ0xS5tbJsUIrKnkSjMVJsE8L9khM-rSUGrJ2VJNXEG6IkyRXOKUQ6X1Qjyedg--_x45DNm-H303vcyUBpOQRTlB6gQVvg_Bc5UdfN06f8wkZL-Ksv-KptLDeXnMWy7_Kmcn-ge8H2AF</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>KeleSl, Nesil</creator><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200401</creationdate><title>Treatment of allergic rhinitis during pregnancy</title><author>KeleSl, Nesil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Adult</topic><topic>Allergens</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Anti-Asthmatic Agents - adverse effects</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Cromolyn Sodium - administration & dosage</topic><topic>Cromolyn Sodium - adverse effects</topic><topic>Cromolyn Sodium - therapeutic use</topic><topic>Female</topic><topic>Health Behavior</topic><topic>Histamine H1 Antagonists - administration & dosage</topic><topic>Histamine H1 Antagonists - adverse effects</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Nasal Decongestants - administration & dosage</topic><topic>Nasal Decongestants - adverse effects</topic><topic>Nasal Decongestants - therapeutic use</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Rhinitis, Allergic, Perennial - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>KeleSl, Nesil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of rhinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KeleSl, Nesil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of allergic rhinitis during pregnancy</atitle><jtitle>American journal of rhinology</jtitle><addtitle>Am J Rhinol</addtitle><date>2004-01</date><risdate>2004</risdate><volume>18</volume><issue>1</issue><spage>23</spage><epage>28</epage><pages>23-28</pages><issn>1050-6586</issn><issn>1945-8924</issn><eissn>1539-6290</eissn><eissn>1945-8932</eissn><abstract>Allergic rhinitis (AR) affecting approximately 20-30% of women in childbearing age can be considered one of the most common group of medical conditions that complicate pregnancy. AR with symptoms of nasal obstruction, sneezing, and itching may require pharmacotherapy. However, there are concerns regarding the safety of different available agents that can be used during pregnancy with respect to both maternal and fetal well being.
The best first-line approach in the management of AR is avoidance of allergens. If environmental modification is ineffective, then the pharmacologic agents should be chosen. For symptoms of rhinorrhea, sneezing, or itching, intranasal cromolyn, with its excellent safety profile, should be considered as first-line therapy. If cromolyn is ineffective or poorly tolerated, first-generation (e.g., chlorpheniramine and tripelennamine) and second generation (e.g., cetirizine and loratadine) antihistamines can be given. Intranasal steroids (e.g., beclomethasone dipropionate, and budesonide) can be added to first-line therapy especially for severe nasal obstruction. There are no epidemiological studies with newer intranasal steroids (e.g., flunisolide, triamcinolone acetonide, fluticasone propionate, and mometasone furoate) during the first trimester of pregnancy. Immunotherapy has not proven to be teratogenic and is clinically useful in improving symptoms. Oral and topical decongestants can be considered as second-line therapy, for short-term relief, when no safer alternative is available.</abstract><cop>United States</cop><pub>SAGE PUBLICATIONS, INC</pub><pmid>15035567</pmid><doi>10.1177/194589240401800106</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-6586 |
| ispartof | American journal of rhinology, 2004-01, Vol.18 (1), p.23-28 |
| issn | 1050-6586 1945-8924 1539-6290 1945-8932 |
| language | eng |
| recordid | cdi_proquest_journals_230846951 |
| source | Sage Journals Online |
| subjects | Administration, Oral Administration, Topical Adult Allergens Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Cromolyn Sodium - administration & dosage Cromolyn Sodium - adverse effects Cromolyn Sodium - therapeutic use Female Health Behavior Histamine H1 Antagonists - administration & dosage Histamine H1 Antagonists - adverse effects Histamine H1 Antagonists - therapeutic use Humans Immunotherapy Nasal Decongestants - administration & dosage Nasal Decongestants - adverse effects Nasal Decongestants - therapeutic use Pregnancy Pregnancy Complications - drug therapy Rhinitis, Allergic, Perennial - drug therapy |
| title | Treatment of allergic rhinitis during pregnancy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-25T20%3A25%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20allergic%20rhinitis%20during%20pregnancy&rft.jtitle=American%20journal%20of%20rhinology&rft.au=KeleSl,%20Nesil&rft.date=2004-01&rft.volume=18&rft.issue=1&rft.spage=23&rft.epage=28&rft.pages=23-28&rft.issn=1050-6586&rft.eissn=1539-6290&rft_id=info:doi/10.1177/194589240401800106&rft_dat=%3Cproquest_cross%3E1350162891%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-e19b9e62e50e36def3e6c845bbdea5ee53d86796a9d29e6c63f65756a4a2a5233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230846951&rft_id=info:pmid/15035567&rfr_iscdi=true |